. Author manuscript; available in PMC: 2020 Oct 10.

Published in final edited form as: J Med Chem. 2019 May 7;62(19):8695–8710. doi: 10.1021/acs.jmedchem.8b01906

Table 1.

Clinical Studies with PF-05089771

Indication	Subjects	Arms	Endpoint	Result
Evoked pain in healthy volunteers⁷⁵	25	PF-05089771 (300 mg), PF-05089771 + pregabalin, pregabalin, ibuprofen, placebo	Thermal, UV, pressure, electrical and cold pain thresholds	Not significantly different than placebo
Diabetic peripheral neuropathy⁷⁶	141	PF-05089771 (150 mg), PF-05089711 + pregabalin, pregabalin, placebo	Daily pain numeric rating (NRS)	Trend toward lower NRS, not statistically significant
Postoperative dental pain⁷⁶	235	PF-05089771 (150–1600 mg), ibuprofen, placebo	Total pain relief, 0–6 hours (TOTPAR[6])	Small statistically-significant effect at 150 mg dose
Inherited erythromelalgia⁷⁷	5	PF-05089771 (1600 mg), placebo, crossover design	Average pain score post dose (PI-NRS)	Lower pain score at 4–5 h and 8–9 h post dose (P < 0.1)
Osteoarthritis of the knee	80	PF-05089771, placebo	Safety, tolerability, pharmacokinetics	Not disclosed